Exploration of Targeted Anti-tumor Therapy

Open Access Original Article

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

Kate M. Moore ... Simon P. Langdon

Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:97–116

DOI: https://doi.org/10.37349/etat.2022.00074

This article belongs to the special issue Endocrine Resistant Breast Cancer

Full Text PDF

2660 72 1

Open Access Case Report

Liver venous deprivation for resection of advanced hilar cholangiocarcinoma—a case report and review of the literature

Radoslava Stoyanova ... Alexander Klaus

Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:90–96

DOI: https://doi.org/10.37349/etat.2022.00073

This article belongs to the special issue Precision Medicine for Cholangiocarcinoma

Full Text PDF

2470 53 1

Open Access Review

Targeting the two-pore channel 2 in cancer progression and metastasis

Kathryn A. Skelding ... Lisa F. Lincz

Published: February 28, 2022 Explor Target Antitumor Ther. 2022;3:62–89

DOI: https://doi.org/10.37349/etat.2022.00072

This article belongs to the special issue Calcium Signaling Apparatus in Cancers

Full Text PDF

3968 71 10

Open Access Review

Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics

Serge Mignani ... Jean-Pierre Majoral

Published: February 25, 2022 Explor Target Antitumor Ther. 2022;3:50–61

DOI: https://doi.org/10.37349/etat.2022.00071

This article belongs to the special issue Gene Delivery Approach to Fight Cancer

Full Text PDF

2579 52 2

Open Access Original Article

B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells

Annabel R. Minton ... Graham Packham

Published: February 25, 2022 Explor Target Antitumor Ther. 2022;3:37–49

DOI: https://doi.org/10.37349/etat.2022.00070

Full Text PDF

4055 83 3

Open Access Review

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

Kira-Lee Koster ... Markus Joerger

Published: February 24, 2022 Explor Target Antitumor Ther. 2022;3:27–36

DOI: https://doi.org/10.37349/etat.2022.00069

This article belongs to the special issue Antibody-Drug Conjugates

Full Text PDF

5555 105 19

Open Access Original Article

Bcl-2-like protein-10 increases aggressive features of melanoma cells

Donatella Del Bufalo ... Simona D’Aguanno

Published: January 30, 2022 Explor Target Antitumor Ther. 2022;3:11–26

DOI: https://doi.org/10.37349/etat.2022.00068

This article belongs to the special issue The Role of Bcl-2 Family Proteins in Cancer Progression and Their Relevance to Cancer Therapy

Full Text PDF

3217 76 5

Open Access Review

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?

Monique Hartley-Brown, Paul Richardson

Published: January 14, 2022 Explor Target Antitumor Ther. 2022;3:1–10

DOI: https://doi.org/10.37349/etat.2022.00067

This article belongs to the special issue Antibody-Drug Conjugates

Full Text PDF

4604 132 6